The funds will be used to evaluate TQL1055, manufactured by Adjuvance, with SARS-CoV2 antigen, manufactured by NIH (National Institutes of Health).
TQL1055 is Adjuvance's novel Saponin vaccine adjuvant. The total funding in this contract is USD 1.47m.
Adjuvance Technologies is a privately held biopharmaceutical company focused on improving health and saving lives through breakthroughs in vaccine adjuvant design.
Its lead adjuvant, TQL1055, is in pre-clinical development for multiple indications in infectious disease, oncology, neurobiology, substance abuse, and allergy.
The National Institutes of Health (NIH), a part of the US Department of Health and Human Services, is the US's medical research agency.
CytoAgents Receives NIH Funding to Accelerate Treatment for Cytokine Storm
Moderna Receives FDA Fast Track Designation for mRNA Vaccine Against Novel Coronavirus
Japanese Ministry of Health Approves Veklury (remdesivir) in Japan for Patients with Severe COVID-19
Moderna and Lonza Team to Manufacture Moderna's Vaccine Against Novel Coronavirus
Integral Molecular awarded USD1m from NIAID to fight COVID-19
Enterin intends to launch randomized Phase 1/2a study in hospitalized COVID-19 patients
Do Mosquitoes and Ticks Transmit COVID-19? The National Pest Management Association Says No
Lilly commences clinical testing of therapies in NIH-led Adaptive COVID-19 treatment trial